… We completed a randomised phase 3 trial to assess the role of preoperative radiotherapy
after induction chemotherapy in patients with IIIA/N2 non-small-cell lung cancer. The addition …

… lung cancer (NSCLC) enrolled in phase III trials. The analysis similarly revealed a very small
increase in patient survival (3.61 days per year) but one that was statistically significant in …

… Phase III Trials The phase III trials initiated for patients with extensive-stage SCLC were
identified through a search of the National Cancer Institute Cancer Therapy Evaluation Program …

… Prior analysis of phase III trials for patients with extensive-stage small-cell lung cancer (SCLC)
revealed that the median of median survival of patients treated on phase III trials and of …

… erlotinib came from phase I/II studies in previously treated patients. In one phase II trial in
NSCLC, … In a large phase III trial in previously treated patients with advanced NSCLC, erlotinib …

… Study results at an interim analysis and lack of efficacy in another phase III trial prompted
early closure of this study. … had stage IIIB disease with T4 primary tumor, 193 had stage IV …

… Aim of this systematic review is to describe QoL adoption and reporting in randomized phase
III trials testing anticancer drugs in lung cancer patients, published between 2012 and 2018 …

… untreated extensive-stage SCLC were included because prior studies have shown higher
… with untreated extensive-stage SCLC, we used a “windowed” Phase II study design, with …

… Study design In a randomized phase III trial, 610 patients with inoperable stage II or III
non–small cell lung cancer were randomly assigned to two different concurrent regimens (…

… We found that the toxicity rates for 3-weekly docetaxel 75 mg/m 2 were generally … phase III
studies, 5,6 although grade 3 to 4 neutropenia was considerably less frequent in our study (21…